Phase 3 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have previously had a solid organ transplant (such as a kidney, liver, heart, lung, pancreas, or small bowel) or a bone marrow/stem cell transplant from a donor.
• People who have been diagnosed with a condition called EBV-positive PTLD (a type of lymphoma linked to the Epstein-Barr virus after transplant), confirmed by a tissue biopsy.
• People whose disease shows up on specific imaging scans (such as PET-CT or MRI) and meets the measurable disease requirements used in this trial.
• People for whom a matched version of the study treatment (tabelecleucel) is available, as confirmed by the trial sponsor.
• People whose PTLD did not respond to, or came back after, treatment with rituximab (alone or combined with chemotherapy).
• People of any age, male or female.
• People who are well enough to carry out some daily activities — this is measured using standard medical scoring tools based on age (confirm with trial site).
• For stem cell transplant recipients only: people whose original condition (such as leukemia) that led to the transplant is currently in remission.
• People whose blood counts and organ function meet the minimum levels required for the trial (confirm with trial site for specific values).
• People (or their legal representative) who are willing and able to give written consent to participate.

Who may not be able to join:

• People who currently have certain other types of lymphoma or blood cancers (such as Burkitt lymphoma, T-cell lymphoma, Hodgkin lymphoma, or others listed in the criteria) that require active treatment.
• People taking high daily doses of steroids (above a certain threshold), or currently receiving methotrexate or a treatment called extracorporeal photopheresis.
• People with PTLD that has spread to the brain or spinal cord that has not yet been treated, or where active chemotherapy or radiation to the brain/spine is still ongoing at the time of enrolment.
• Stem cell transplant recipients who currently have moderate or severe graft-versus-host disease (a complication where donor cells attack the body).
• People who have recently received certain immunotherapy drugs called checkpoint inhibitors (such as ipilimumab, pembrolizumab, or nivolumab) within a specific time window before enrolment.
• Stem cell transplant recipients who currently have an active adenovirus infection in the blood.
• People who currently need machines or medications to support their breathing or blood pressure.
• People who received a specific type of immune-suppressing therapy (antithymocyte globulin or similar) within 4 weeks before enrolment.
• People who received certain specialised T-cell or B-cell therapies related to EBV or transplant within 8 weeks before enrolment (confirm with trial site for specifics).
• People who are pregnant or breastfeeding, or people of childbearing potential (male or female) who are unwilling to use a highly effective form of contraception during the trial.
• People who would be unable to follow the procedures required by the study.
• People with any other medical condition that the treating doctor believes could put them at risk or prevent them from completing the trial.

Important: Always verify eligibility with the trial site directly before applying.